ROLE OF ENDOTHELIAL INFLAMMATION IN DEMYELINATING DISEASES OF THE CENT
ROLE OF ENDOTHELIAL INFLAMMATION IN DEMYELINATING DISEASES OF THE CENTRAL NERVOUS SYSTEM
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Dimethyl fumarate
Kelch-like ECH-associated protein 1 inhibitor
What it measured
Main measures
Finding a prognostic biomarker
Blood or spinal fluid markers
Other measures (1)
2.2.1. Primary Endpoint
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: Inclusion Criteria Exclusion: Exclusion Criteria
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Screening for a prognostic biomarker regarding MS
Papers
Results
Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.J Neurol Neurosurg Psychiatry · 2019
Loading reviews and guidelines…
Related trials
- A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Part
Running, not recruiting
Still running
- Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Scle
Phase 4 · Status unknown
No results found
- Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnorm
Completed
No results found
- Relationship Between Oral DMT Burden and Adherence in MS
Status unknown
No results found
- Study to Compare GI Tolerability Following Oral Administration of Bafi
Phase 1 · Completed
No results found
- Teriflunomide Tecfidera LMCE
Completed
Paper found, not read
History
Started
Mar 2014